• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.

作者信息

Striepe Kristina, Jumar Agnes, Ott Christian, Karg Marina V, Schneider Markus P, Kannenkeril Dennis, Schmieder Roland E

机构信息

From Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.

出版信息

Circulation. 2017 Sep 19;136(12):1167-1169. doi: 10.1161/CIRCULATIONAHA.117.029529.

DOI:10.1161/CIRCULATIONAHA.117.029529
PMID:28923906
Abstract
摘要

相似文献

1
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.选择性钠-葡萄糖协同转运蛋白2抑制剂恩格列净对2型糖尿病患者血管功能和中心血流动力学的影响。
Circulation. 2017 Sep 19;136(12):1167-1169. doi: 10.1161/CIRCULATIONAHA.117.029529.
2
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
3
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
4
Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.群体药代动力学-药效学分析以表征恩格列净对1型糖尿病患者肾葡萄糖阈值的影响
J Clin Pharmacol. 2018 May;58(5):640-649. doi: 10.1002/jcph.1051. Epub 2017 Dec 18.
5
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.恩格列净对 2 型糖尿病患者冠状动脉微血管功能的影响：一项随机、安慰剂对照交叉研究。
PLoS One. 2022 Feb 11;17(2):e0263481. doi: 10.1371/journal.pone.0263481. eCollection 2022.
6
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.恩格列净联合二甲双胍治疗改善 1 型糖尿病患者的动脉功能。
Cardiovasc Diabetol. 2018 Dec 3;17(1):153. doi: 10.1186/s12933-018-0797-6.
7
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).一项评价恩格列净对心血管高危 2 型糖尿病患者心肌灌注、功能和代谢影响的随机对照临床试验设计（SIMPLE 试验）。
BMJ Open. 2019 Nov 27;9(11):e029098. doi: 10.1136/bmjopen-2019-029098.
8
Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.来自 EMPA-REG OUTCOME 试验的分析表明，恩格列净可能有助于预防 2 型糖尿病患者慢性肾脏病的进展，而与改变肾内血液动力学的药物无关。
Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21.
9
The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.恩格列净对2型糖尿病患者氧化核酸修饰的影响：一项随机、双盲、安慰剂对照试验的方案
BMJ Open. 2017 May 9;7(5):e014728. doi: 10.1136/bmjopen-2016-014728.
10
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.一项评估恩格列净对内皮功能影响的多中心安慰剂对照双盲随机试验的原理与设计：EMBLEM试验
Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8.

引用本文的文献

1
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.达格列净对2型糖尿病和/或慢性肾脏病患者钠排泄、血压及容量状态的影响：DAPASALT试验
Diabetes Obes Metab. 2025 Aug;27(8):4415-4426. doi: 10.1111/dom.16478. Epub 2025 May 30.
2
Sodium-glucose cotransporter-2 inhibitor use in type 2 diabetes mellitus is associated with a lower rate of atrial arrhythmias in a hospitalized real-world population.在住院的真实世界人群中，2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂与较低的房性心律失常发生率相关。
Heart Rhythm O2. 2024 Dec 19;6(3):299-306. doi: 10.1016/j.hroo.2024.12.004. eCollection 2025 Mar.
3
Early vascular aging ambulatory score in acute ischemic stroke.
急性缺血性卒中的早期血管衰老门诊评分
NPJ Aging. 2025 Feb 21;11(1):13. doi: 10.1038/s41514-025-00202-7.
4
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases.心血管疾病中SGLT2抑制剂的文献计量学与可视化分析
Front Pharmacol. 2024 Oct 30;15:1437760. doi: 10.3389/fphar.2024.1437760. eCollection 2024.
5
Advanced vascular aging and outcomes after acute ischemic stroke: a systematic review and meta-analysis.血管老化与急性缺血性脑卒中结局的相关性：系统评价和荟萃分析。
J Hum Hypertens. 2024 Oct;38(10):676-686. doi: 10.1038/s41371-024-00961-y. Epub 2024 Sep 24.
6
Is GFR decline induced by SGLT2 inhibitor of clinical importance?SGLT2 抑制剂引起的肾小球滤过率下降是否具有临床重要性？
Cardiovasc Diabetol. 2024 May 29;23(1):184. doi: 10.1186/s12933-024-02223-0.
7
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.钠-葡萄糖协同转运蛋白2抑制剂：从降血糖到心血管获益
Cardiovasc Res. 2024 Apr 30;120(5):443-460. doi: 10.1093/cvr/cvae047.
8
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.SGLT2 抑制剂恩格列净可促进糖尿病小鼠卒中后的功能恢复。
Cardiovasc Diabetol. 2024 Feb 29;23(1):88. doi: 10.1186/s12933-024-02174-6.
9
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的系统和器官特异性抗炎作用。
Trends Endocrinol Metab. 2024 May;35(5):425-438. doi: 10.1016/j.tem.2024.02.003. Epub 2024 Feb 29.
10
Sodium-Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension.钠-葡萄糖协同转运蛋白2抑制剂：治疗肥胖相关性高血压的新应用
Diabetes Metab Syndr Obes. 2024 Jan 26;17:407-415. doi: 10.2147/DMSO.S446904. eCollection 2024.